Wegovy
HealthNovo Nordisk became Europe’s most valuable company with the rise of Wegovy and Ozempic, but it’s facing stiff competition from a local pharma rival
By Christian Wienberg and BloombergDecember 13, 2023
FinanceRoche pushes to catch up to Novo Nordisk’s Wegovy with $3.1bn deal for obesity drugmaker Carmot
By Paula Doenecke and BloombergDecember 4, 2023
HealthPfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
HealthWegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
By Jonel Aleccia and The Associated PressNovember 20, 2023
RetailSo many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug
By Ryan HoggNovember 16, 2023
RetailScientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports
By Prarthana PrakashNovember 13, 2023
HealthA ‘game-changing’ study backs Wegovy use to cut heart attacks and strokes: ‘This is not just about weight and appearance’
By Madison Muller, Naomi Kresge and BloombergNovember 11, 2023
RetailNovo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
By Ryan HoggNovember 9, 2023
By Ryan HoggNovember 6, 2023
HealthNovo Nordisk isn’t alone: Sales of Ozempic rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze
By Prarthana PrakashNovember 3, 2023
HealthBrands like Walmart and Nestle are right to worry about Wegovy. Novo Nordisk sold $900m of the weight loss drug last quarter—and 95% was in the U.S.
By Ryan HoggNovember 2, 2023
Most Popular
